Menderes, G., Bonazzoli, E., Bellone, S., Black, J., Predolini, F., Pettinella, F., . . . Santin, A. D. (2017). SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clin Cancer Res.
Citação norma ChicagoMenderes, Gulden, et al. "SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma With HER2/Neu Expression." Clin Cancer Res 2017.
Citação norma MLAMenderes, Gulden, et al. "SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma With HER2/Neu Expression." Clin Cancer Res 2017.